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MaBACKGROUND Cardiac dysfunction inﬂuences candidate selection for kidney transplantation. There is a paucity of data
regarding predictors of myocardial recovery following kidney transplantation and long-term outcomes.
OBJECTIVES The purpose of this study was to identify the extent of reverse remodeling in our kidney transplant
population and the predictors of such changes, and to assess outcomes in these patients.
METHODS Wereviewed232patientswhounderwent kidney transplantation at theClevelandClinic from2003 to2013 and
who had baseline and post-transplant echocardiograms; patients with simultaneous heart transplantation were excluded.
RESULTS Post-transplantation mean left ventricular ejection fraction (LVEF) improved in those with LV dysfunction
(increased from 41% to 50%; p < 0.0001; n ¼ 66). There was signiﬁcant improvement in other parameters, including
diastolic function, LV end-diastolic dimension, LV mass, and right ventricular systolic pressure. After adjusting for
multiple clinical variables, increased hemoglobin following transplantation was associated with an improved LVEF
(odds ratio: 1.50; 95% conﬁdence interval [CI]: 1.07 to 2.14; p ¼ 0.016) and reduced mortality (hazard ratio [HR]: 0.65;
95% CI: 0.49 to 0.87; p ¼ 0.004). An improved LVEF $10% predicted survival independently of a pre-transplantation
LVEF (HR: 0.46; 95% CI: 0.21 to 0.93; p ¼ 0.031).
CONCLUSIONS Kidney transplantation is associated with improved cardiac structure and function. A rise in
post-transplantation hemoglobin was a signiﬁcant factor associated with such changes, in addition to conferring a
survival advantage. (J Am Coll Cardiol 2015;66:1779–87) © 2015 by the American College of Cardiology Foundation.I n patients with end-stage renal disease (ESRD),progressive cardiorenal compromise often re-sults in the development of adverse cardio-
vascular outcomes, which is one of the leading
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pathophysiologic processes play a contributing
role. Although patients with ESRD have a highm the *Department of Cardiovascular Medicine, Cleveland Clinic, Cl
veland Clinic, Cleveland, Ohio; zApex Heart Clinic, Gleneagles Hospital,
pertension, Cleveland Clinic, Cleveland, Ohio. This research was support
1HL103931). The authors have reported that they have no relationships r
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
nuscript received March 13, 2015; revised manuscript received July 30, 20prevalence of “conventional” cardiovascular risk
factors, including hypertension, diabetes, and hyper-
lipidemia, these do not account for all the cardiovas-
cular risks (2). Other contributing factors include
hemodynamic overload from volume and pressure,
anemia, arteriovenous shunts, and arterial remodel-
ing, as well as biochemical mediators and uremic
toxins, such as alterations in calcium, phosphate,
parathyroid hormone, urea, homocysteine, and endo-
thelin (3).eveland, Ohio; yDepartment of Internal Medicine,
Singapore; and the xDepartment of Nephrology and
ed by a grant from the National Institutes of Health
elevant to the contents of this paper to disclose.
ntin Fuster.
15, accepted August 4, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
BSA = body surface area
BMI = body mass index
CKD = chronic kidney disease
DBP = diastolic blood pressure
eGFR = estimated glomerular
ﬁltration rate
ESRD = end-stage renal
disease
HF = heart failure
LV = left ventricular
LVDd = left ventricular end-
diastolic dimension
LVEF = left ventricular ejection
fraction
RVSP = right ventricular
systolic pressure
SBP = systolic blood pressure
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1780Despite signiﬁcant progress in the care of
patients with heart failure (HF), patients with
ESRD and concomitant cardiac dysfunction
are generally considered less suitable candi-
dates for kidney transplantation due to
the increased risk of operative morbidity
and mortality. Nevertheless, an emerging
concept has challenged this notion that car-
diac dysfunction is a forbidding comorbidity.
Reports have shown that kidney trans-
plantation may actually improve cardiac
function, as measured by serial radionuclide
ventriculography (4), a factor that should be
taken into consideration when evaluating
these patients. Herein, our objective is to
describe the longitudinal experience of
cardiac remodeling in our kidney trans-
plantation population, their respective mor-
tality risk following transplantation, and their
propensity for reverse remodeling, as well aselements that inﬂuence these changes.SEE PAGE 1788METHODS
STUDY POPULATION. We retrospectively reviewed
our single-center experience of adult patients with
ESRD who underwent living donor and cadaveric kid-
ney transplantation at the Cleveland Clinic between
January 2003 andDecember 2013 andwho had pre- and
post-transplant transthoracic echocardiograms. All
patients were in chronic stable condition and were
carefully reviewed by an interdisciplinary committee
that deemed them eligible for transplantation after
weighing the risks and beneﬁts. All transplantation
recipients received a protocol-driven standardized
post-transplantation medical regimen, including
tacrolimus, mycophenolate mofetil, and prednisone.
We excluded those who did not have post-
transplantation follow-up documented in their elec-
tronic medical record or those with simultaneous
heart–kidney transplantation. The Cleveland Clinic
Institutional Review Board approved the study.
Demographic, clinical, echocardiographic, and
laboratory data were obtained directly from the
electronic medical record. Estimated glomerular
ﬁltration rate (eGFR) was calculated using the Modi-
ﬁcation of Diet in Renal Disease equation (5). Refer-
ence values for echocardiographic parameters were
deﬁned on the basis of the recent American Society of
Echocardiography (ASE) guidelines (6) as follows:
mild systolic dysfunction, left ventricular ejection
fraction (LVEF) #51% for men and #53% for women,but >40%; moderate dysfunction, LVEF #40% for
both sexes; abnormal LV mass indexed to body sur-
face area (BSA) >115 g/m2 in men and >95 g/m2
in women; and severely abnormal LV mass/BSA
>148 g/m2 in men and >121 g/m2 in women. Hy-
pertension was deﬁned by a cutoff of $130/80 mm Hg
(7), and alternatively as $140/90 mm Hg on the basis
of the more recent Eighth Joint National Committee
(JNC-8) guidelines (8). Anemia was deﬁned as
hemoglobin <13 g/dl in men and <12 g/dl in women
on the basis of KDIGO (Kidney Disease–Improving
Global Outcomes) guidelines for patients with chronic
kidney disease (CKD) (9). These parameters were
obtained from the most recent pre-transplantation
and 12-month post-transplantation ofﬁce visits. One
exception was echocardiographic data, the timing of
which could not be controlled for in this retrospective
study. Echocardiograms were obtained during the
pre-transplantation evaluation, with the most recent
one taken into account, and obtained at the time
closest to 12 to 24 months post-transplantation
(see Results section).
ASSESSMENT OF CARDIAC STRUCTURE AND FUNCTION.
All echocardiograms were performed at our institu-
tion. For each echocardiographic examination, inter-
ventricular septal diameter, posterior wall diameter,
and left ventricular end-diastolic dimension (LVDd)
were measured according to ASE recommendations
(6). LVEF was calculated by the biplane Simpson
method. LV mass, calculated using the ASE equation,
was deﬁned as: 0.8  (1.04  [interventricular septal
diameter þ posterior wall diameter þ LVDd]3 –
[LVDd3]) þ 0.6, and was indexed to BSA. LV diastolic
functionwas graded as either normal or as stages I to IV
on the basis of mitral inﬂow proﬁles and tissue Doppler
imaging. Right ventricular systolic pressure (RVSP)
was estimated from the tricuspid regurgitation veloc-
ity using the modiﬁed Bernoulli equation.
STATISTICAL ANALYSIS. Continuous variables were
reported as mean  SD if normally distributed or as
median and interquartile range (IQR) if non-normally
distributed. Normality was assessed by the Shapiro-
Wilk W test. Differences in clinical variables were
assessed using the Student t test or analysis of vari-
ance. Linear regression analysis was used to analyze
the association between clinical variables and reverse
remodeling. Odds ratio (OR) for predicting clinical
outcomes was calculated using logistic regression
analysis and evaluated according to the likelihood
ratio test. Kaplan-Meier survival analysis was used to
compare unadjusted survival, and the log-rank test
assessed the differences between groups. The Cox
proportional hazards model was used to test for
TABLE 1 Baseline Patient Characteristics
Characteristics
Pre- and Post-Tx TTE
(n ¼ 232)
Pre-Tx TTE
(n ¼ 1,143)
No TTE
(n ¼ 322)
p
Value
Transplant age, yrs 54  12 50  12 44  13 <0.001
Male 145 (63) 718 (63) 191 (59) 0.475
White race 156 (67) 856 (75) 246 (76) 0.129
BMI, kg/m2 28  6 27  5 27  6 0.081
Renal condition*
Diabetes 72 (31) 366 (32) 47 (15) <0.001
Hypertension 54 (23) 225 (20) 81 (25) 0.034
Glomerulonephritis 36 (16) 229 (20) 83 (26) 0.011
Polycystic kidney disease 14 (6) 138 (12) 41 (13) 0.022
Pre-emptive transplantation 39 (17) 250 (22) 87 (27) 0.015
Hemodialysis (among dialysis
patients)
163 (84) 673 (75) 155 (66) 0.011
Arteriovenous access 123 (75) 507 (75) 103 (66) 0.044
Median dialysis duration, days 778 (239-1,741) 893 (377-1,626) 644 (298-1,108) <0.001
Combined transplantation
(liver or pancreas)
25 (11) 164 (14) 23 (7) <0.001
Comorbidities
Diabetes 107 (46) 469 (41) 73 (22) <0.001
Hypertension 191 (82) 853 (75) 226 (70) 0.031
Hyperlipidemia 132 (57) 381 (33) 72 (22) <0.001
Coronary artery disease 61 (26) 148 (13) 15 (5) <0.001
Heart failure 72 (31) 132 (12) 6 (2) <0.001
LVEF 54  10 57  8 <0.001
LV dysfunction† 66 (28) 178 (16) <0.001
Values are mean  SD, n (%), median (interquartile range). *Some patients had combined diabetic and
hypertensive nephropathy. †Reference values deﬁned by American Society of Echocardiography guidelines (6).
BMI ¼ body mass index; BSA ¼ body surface area; LV ¼ left ventricular; LVEF ¼ left ventricular ejection
fraction; TTE ¼ transthoracic echocardiogram; Tx ¼ transplant.
FIGURE 1 Patient Inclusion and Exclusion
Adult Kidney transplant, 2003–2013 (n=1697)
Pre-transplant echo (n=1375)
Baseline systolic dysfunction (n=244)
Excluded (n=1465)
Baseline abnormalities
Systolic dysfunction (n=66)
LVH based on LVM/BSA (n=151)
Absence of pre– or post–transplant echo
  or follow-up (n=1459)
Included (n=232)
Combined heart/kidney transplant (n=6)
Of 1,697 kidney transplantation patients, 232 patients were eventually included in this
study. LVH ¼ left ventricular hypertrophy; LVM/BSA ¼ left ventricular mass indexed to
body surface area.
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1781independent predictors of mortality. All reported
p values are from 2-sided tests, and a p value <0.05
was considered statistically signiﬁcant. Statistical
analyses were performed using JMP (version 11.2.0;
SAS Institute, Cary, North Carolina).
RESULTS
Of the 1,697 adult patients who underwent kidney
transplantation, we identiﬁed 232 patients who ful-
ﬁlled the inclusion and exclusion criteria (Figure 1).
Per the baseline demographic data (Table 1), the pre-
dominant etiology of ESRD was diabetes (31%) and
hypertension (23%). The majority of patients were
dialysis-dependent (mostly intermittent hemodialy-
sis), and the median duration of dialysis was 778 days
(IQR: 239 to 1,741 days). Pre-emptive transplantation
occurred in 17% of patients. Simultaneous kidney–
pancreas or kidney–liver transplantation accounted
for 11% of the cohort. The pre-transplantation echo-
cardiogram was performed at a median duration
of 257 days (IQR: 125 to 460 days) versus the post-
transplantation echocardiogram, which occurred at a
median of 422 days (IQR: 241 to 735 days). The base-
line echocardiogram revealed a reduced LVEF in 28%
of patients (taking all 1,375 patients who underwent
pre-transplantation echocardiography into account,
18% had LV dysfunction). An abnormal LV mass/BSA
was identiﬁed in 65% of patients.
As expected, hypertension was a prevalent co-
morbidity, accounting for 82% of our cohort, and
71% of patients had anemia.
REVERSE REMODELING FOLLOWING KIDNEY
TRANSPLANTATION. The changes in echocardio-
graphic, clinical, and laboratory variables in the
post-transplantation period are listed in Table 2. Dur-
ing the study, none of these patients underwent cor-
onary revascularization or cardiac resynchronization
therapy to explain the improvements seen, and only 1
patient had an aortic valve replacement. LVEF im-
proved by 9  13% in those with any degree of systolic
dysfunction (p < 0.0001; n ¼ 66), and by 15  13% in
those with moderate systolic dysfunction (p < 0.0001;
n ¼ 28). Regression in LV mass was noted following
transplantation. LV mass/BSA improved by 20 g/m2
(p < 0.0001; n ¼ 151) in those with baseline abnor-
malities. Statistically signiﬁcant improvements in
LVDd, wall diameter, diastolic function, and RVSP
were similarly observed (Table 2). Those with a
baseline systolic blood pressure (SBP) $130 mm Hg or
diastolic blood pressure (DBP) $80 mm Hg demon-
strated an 18  26 mm Hg and 10  17 mm Hg
improvement, respectively (p < 0.0001). These results
TABLE 2 Post-Transplantation Outcomes
Variable Pre-Transplantation Post-Transplantation p Value
LVEF
All patients 53  10 56  10 0.002
Baseline LVSD (n ¼ 66)* 41  10 50  12 <0.0001
Baseline moderate LVSD* (n ¼ 28) 32  7 47  14 <0.0001
LVM/BSA, g/m2
All patients 132  46 125  42 0.032
Baseline LVH* (n ¼ 151) 154  40 134  45 <0.0001
Baseline severe LVH* (n ¼ 90) 176  36 138  42 <0.0001
LVDd, cm
All patients 4.8  0.7 4.7  0.7 0.005
Baseline $5.6 (n ¼ 33) 6.0  0.4 5.0  0.8 <0.0001
IVS diameter, cm
All patients 1.4  0.3 1.4  0.3 0.984
Baseline $1.2 (n ¼ 180) 1.5  0.2 1.4  0.3 <0.001
PW diameter, cm
All patients 1.2  0.3 1.2  0.3 0.974
Baseline $1.2 (n ¼ 140) 1.4  0.2 1.3  0.3 <0.0001
RVSP, mm Hg
All patients 35  11 34  12 0.728
Baseline $40 (n ¼ 35) 48  8 38  15 <0.001
Diastolic dysfunction
Stage 2 56 (24) 50 (22)
Stage 3 7 (3) 6 (3)
Blood pressure, mm Hg
All patients’ SBP 136  25 132  22 0.026
All patients’ DBP 76  13 74  13 0.080
Baseline SBP $130 (n ¼ 130) 152  19 134  22 <0.0001
Baseline SBP $140 (n ¼ 95) 159  18 137  23 <0.0001
Baseline DBP $80 (n ¼ 86) 88  10 78  14 <0.0001
Baseline DBP $90 (n ¼ 28) 99  11 81  13 <0.0001
Hemoglobin, g/dl
All patients 11.8  1.5 12.3  2.0 <0.001
Baseline anemia† (n ¼ 165) 11.1  1.1 12.2  2.1 <0.0001
Medications
Beta-blocker 141 (61) 148 (64) 0.733
ACE inhibitor or ARB 67 (29) 37 (16) <0.001
Aldosterone antagonist 0 (0) 3 (1) 0.083
Hydralazine 24 (10) 19 (8) 0.354
Nitrate 21 (9) 17 (7) 0.347
Mortality
1 yr 15 (7)
3 yrs 25 (11)
5 yrs 33 (14)
Values are mean  SD or n (%). *Reference values deﬁned by American Society of Echocardiography guidelines
(6). †Deﬁned as hemoglobin <13 g/dl in men and <12 g/dl in women (9).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; DBP ¼ diastolic blood pressure;
IVS ¼ interventricular septum; LVDd ¼ left ventricular end-diastolic dimension; LVH ¼ left ventricular hyper-
trophy; LVM/BSA ¼ left ventricular mass indexed to body surface area; LVSD ¼ left ventricular systolic
dysfunction; PW ¼ posterior wall; RVSP ¼ right ventricular systolic pressure; SBP ¼ systolic blood pressure; other
abbreviations as in Table 1.
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was used.
Anemia and changes in hemoglobin were closely
associated with changes in cardiac structure and
function. In patients with pre-transplantation anemia,post-transplantation hemoglobin improved by 1.1 g/
dl (p < 0.0001). Table 3 lists the correlation between
clinical variables and reverse remodeling. Changes
in hemoglobin showed correlation with changes in
LVEF (in all 232 patients: coefﬁcient: 1.22; 95% con-
ﬁdence interval [CI]: 0.61 to 1.83; p < 0.001; in those
with baseline LV dysfunction: coefﬁcient: 2.17; 95%
CI: 0.94 to 3.40; p < 0.001) (Central Illustration).
In addition, multiple factors were correlated with
LV mass regression, including post-transplantation
improvements in hemoglobin, SBP, DBP, and lower
baseline body mass index (BMI). Change in hemo-
globin was the only independent factor associated
with improved LVEF of $10% using logistic regres-
sion analysis. This held true when corrected for
multiple demographic parameters, including age at
transplantation, sex, race, and BMI (OR: 1.68; 95% CI:
1.20 to 2.39; p ¼ 0.002), as well as clinical factors,
including dialysis duration, eGFR at 12 months, and
changes in SBP and DBP (OR: 1.50; 95% CI: 1.07 to
2.14; p ¼ 0.016).
CLINICAL OUTCOMES. Unadjusted mortality was
higher in patients with an abnormal baseline
LVEF, as assessed in all 1,375 patients who under-
went pre-transplantation echocardiography (log-rank
p < 0.001) (Figure 2A). Nevertheless, despite pre-
transplantation systolic dysfunction, those who had
improved LVEF of $10% had similar mortality out-
comes with those with normal pre-transplantation
LV function (log-rank p ¼ 0.120) (Figure 2B). Changes
in hemoglobin predicted improved survival when
adjusted for demographic and clinically relevant vari-
ables, independent of pre-transplantation LVEF or
post-transplantation improvement in LVEF (hazard
ratio: 0.65; 95% CI: 0.49 to 0.87; p ¼ 0.004) (Table 4).
DISCUSSION
We observed an overall favorable impact of kidney
transplantation on cardiac structure and function,
with a corresponding improvement in long-term
survival seen with reverse remodeling in kidney
transplantation recipients with baseline cardiac dys-
function. Speciﬁcally, LV systolic dysfunction was not
uncommonly observed in patients undergoing kidney
transplantation; it was seen in 1 of 6 patients in
this contemporary series of patients who underwent
echocardiographic evaluation. Although the presence
of baseline LV systolic dysfunction was associated
with poorer overall long-term outcomes following
kidney transplantation, improvement of LVEF $10%
following kidney transplantation in patients with un-
derlying LV systolic dysfunction was associated with
better long-term outcomes. Another key ﬁnding was
TABLE 3 Correlation Between Clinical Variables and Reverse Remodeling*
Variable
D LVEF D LVM/BSA
Coefﬁcient (95% CI) p Value Coefﬁcient (95% CI) p Value
Age at transplantation –0.03 (–0.16 to 0.08) 0.545 –0.20 (–0.75 to 0.34) 0.463
BMI –0.22 (–0.48 to 0.04) 0.095 1.34 (0.14 to 2.53) 0.029
Dialysis duration 0.00 0.00
eGFR at 12 months 0.06 (0.01 to 0.11) 0.017 –0.13 (–0.36 to 0.10) 0.260
D SBP –0.03 (–0.08 to 0.02) 0.281 0.63 (0.43 to 0.83) <0.0001
D DBP –0.07 (–0.16 to 0.02) 0.115 0.76 (0.38 to 1.15) <0.001
D Hemoglobin 1.22 (0.61 to 1.83) <0.001 –7.76 (–10.40 to –5.13) <0.0001
*By linear regression.
eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in Tables 1 and 2.
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was identiﬁed as a major contributor to both reverse
remodeling and prognosis. Taken together, our pre-
sent ﬁndings imply that metabolic factors associated
with ESRD likely contribute to cardiac dysfunction,
and that structural and functional parameters of
cardiac dysfunction may reverse with metabolic
improvement following kidney transplantation.
Patients with ESRD and underlying LV systolic
dysfunction showed remarkable and consistent im-
provements in LVEF following kidney transplanta-
tion, with a mean increase of 15% in those with
a baseline LVEF #40%. Ventricular dilation, as
assessed by LVDd, improved, and LV hypertrophy, as
assessed by LV mass, substantially regressed post-
transplantation. Moreover, positive changes were
seen in diastolic function and RVSP in the post-
transplantation period.
A few previous studies demonstrated positive
changes in LV systolic function following kidney
transplantation, albeit in very small cohorts (10–13).
Our ﬁndings are consistent with ﬁndings from WaliCENTRAL ILLUSTRATION Reverse Remodeling and Kidne
Change in Hemoglobin
Hawwa, N. et al. J Am Coll Cardiol. 2015; 66(16):1779–87.
In patients who have undergone kidney transplantation, the need exists
exploring the relationship between the change in left ventricular ejection
between the changes in these 2 parameters in (A) all patients, D LVEF ¼
D LVEF ¼ (2.2  D hemoglobin) þ 6.9 (p < 0.001).et al. (4) more than a decade ago, who identiﬁed
103 patients with LV systolic dysfunction by radionu-
clide ventriculography gated-blood pool scan; these
patients had signiﬁcant improvement in their LVEF
in the post-transplantation period. Similarly, other
studies showed improvements in LV mass post-
transplantation (14), as well as a correlation betweeny Transplantation: Relationships Between Change in LVEF and
to gather data on predictors of myocardial recovery post-transplantation. In
fraction (LVEF) and the change in hemoglobin, there were signiﬁcant correlations
(1.2  D hemoglobin) þ 1.6 (p < 0.001), and in patients with (B) LV dysfunction,
FIGURE 2 Impact of Impaired Pre-Transplantation LVEF on Post-Transplantation Clinical Outcomes
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The Kaplan-Meier curves demonstrated (A) a signiﬁcant difference in survival on the basis of baseline left ventricular ejection fraction
(LVEF), but (B) no signiﬁcant difference in survival in the subgroup of patients who underwent reverse remodeling. In the latter analysis,
censor time was calculated from the date of post-transplantation echocardiography and not date of transplantation, to reduce possible
confounding.
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largest and most contemporary study to address
this question to date, we demonstrated a similar
correlation; in addition, we identiﬁed correlations be-
tween LV mass regression and DBP and lower baseline
BMI.
An understanding of cardiorenal interactions is
paramount in appreciating the pathophysiological
processes that explain such reverse remodeling (16).
Hemodynamic abnormalities in ESRD result in
increased afterload, a phenomenon that had beenconsidered the primary driver for cardiac dysfunction.
A multitude of factors contribute to this phenomenon,
including interdialytic volume overload, elevated
blood pressure, and decreased vessel compliance
(17). Nevertheless, it is the nonhemodynamic de-
rangements that occur in ESRD, including anemia (18),
secondary hyperparathyroidism (19), overactivity of
the renin-angiotensin-aldosterone system (20,21), as
well as the presence of uremic toxins (22), that likely
contribute to a hostile inﬂammatory milieu for the
myocardium. Ultimately, cardiac dysfunction ensues,
TABLE 4 Clinical Predictors of Mortality
Predictors Hazard Ratio* (95% CI) p Value
Pre-transplantation LVEF† 0.73 (0.67–0.81) <0.001
Pre-transplantation LVM/BSA 1.20 (0.95–1.50) 0.129
Pre-transplantation LVDd 1.25 (0.96–1.60) 0.090
Multivariable model (corrected for age, sex, race, dialysis duration, eGRF at 12 months)‡
Pre-transplant LVEF 0.61 (0.49–0.78) <0.001
Improved LVEF $10% 0.46 (0.21–0.93) 0.031
D Hemoglobin 0.65 (0.49–0.87) 0.004
*Hazard ratio per 1 SD increment for continuous variables. †Pre-transplantation LVEF was assessed in all
1,375 patients who had a pre-transplantation echocardiogram. ‡Censor time was calculated from the date of
post-transplantation echocardiography and not date of transplantation, to reduce possible confounding.
Abbreviations as in Tables 1 to 3.
J A C C V O L . 6 6 , N O . 1 6 , 2 0 1 5 Hawwa et al.
O C T O B E R 2 0 , 2 0 1 5 : 1 7 7 9 – 8 7 Reverse Remodeling and Kidney Transplantation
1785further activating neurohormonal pathways, and
culminating in the vicious cycle of cardiorenal syn-
drome. Although there may be a point at which the
uremic milieu induces irreversible cardiac damage,
our study theoretically demonstrates the continued
overall beneﬁt to the heart following kidney trans-
plantation, despite being preceded by dialysis for a
median duration of >2 years.
There is a paucity of data on factors associated
with reverse remodeling following kidney trans-
plantation. In our study, hemoglobin was a signiﬁcant
predictor of improved LVEF and LV mass in the post-
transplantation period (Central Illustration). This
improvement in anemia translated into superior out-
comes. Despite correcting for important clinical vari-
ables (including baseline LVEF, post-transplantation
improvement in LVEF, and post-transplantation
eGFR), improved hemoglobin remained an indepen-
dent factor associated with reduced mortality.
Although it is not possible to determine causality in
this observational study, the impact of anemia on
cardiac structure and clinical outcomes has
been extensively analyzed. Multiple studies have
demonstrated anemia to be a predictor of mortality
in the HF population (23–25). In addition, an in-
verse correlation was noted between changes in
hemoglobin and LV mass on cardiac magnetic
resonance (26).
The interconnected relationship between CKD, HF,
and anemia has been referred to as the “cardiorenal
anemia syndrome” (27). The predominant etiology of
anemia in this setting is a combination of reduced
erythropoietin production and function related to
CKD and the inﬂammatory state of HF, medication-
related inhibition of the pro-erythropoetic effects of
angiotensin, and disturbances in iron metabolism
(28). Iron deﬁciency in patients with HF is a highly
prevalent, but often overlooked condition. Although
its presence may be suspected in the setting of
anemia, it should be noted that in 1 study, 32% of
nonanemic HF patients were iron deﬁcient (29).
Randomized placebo-controlled trials have assessed
intravenous iron in the setting of HF. The recent
CONFIRM-HF (Ferric Carboxymaltose Evaluation on
Performance in Patients With Iron Deﬁciency in
Combination With Chronic Heart Failure) trial
identiﬁed improvements in functional capacity,
symptoms, quality of life, and reduced risk of HF
hospitalization (30). Importantly, these beneﬁts
were irrespective of hemoglobin, highlighting the
potential adverse nature of iron deﬁciency inde-
pendently of anemia. Other trials have similarly
demonstrated improved symptoms, health status
measures, N-terminal pro–B-type natriuretic peptide,peak maximum oxygen consumption, and improve-
ments in cardiac and renal function (31–33).
Patients with baseline systolic dysfunction had
expected worse outcomes on the basis of unadjusted
analyses in our study. However, we highlighted
a salient point; speciﬁcally, those who underwent
reverse remodeling fared no worse than those
with normal pre-transplantation LVEF. Therefore,
impaired cardiac function should not necessarily
preclude a patient from undergoing kidney trans-
plantation, especially in the absence of other criteria
that indicate the presence of underlying advanced HF
(e.g., severe functional impairment or hemodynamic
compromise). Continued efforts should be made to
identify those factors that might predict reverse
remodeling.
STUDY LIMITATIONS. One of the limitations of the
study is its observational nature, which inherently
may have resulted in some bias. This study cohort
only included those selected for kidney trans-
plantation and those who survived during the
treatment period to allow both pre- and post-
transplantation echocardiography; this might have
inﬂuenced the prognostic conclusions that can be
drawn. However, we did use the date of post-
transplantation echocardiography for censoring to
reduce possible confounding. Moreover, we could
not control for the timing of echocardiograms.
Because of the high prevalence of cardiac structural
abnormalities in ESRD and variations in intravas-
cular volume in dialysis, echocardiography may have
some limitations in this population (34). Cardiac
magnetic resonance is considered the “gold stan-
dard” for assessing cardiac dimensions and
mass, because it is independent of geometric as-
sumptions (35). However, considering its availability
and practicality, echocardiography remains an im-
portant clinical and research tool when assessing
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with mild to moderate ventricular dysfunc-
tion, cardiac structure and function can improve
following kidney transplantation concurrent with an
improvement in anemia.
TRANSLATIONAL OUTLOOK: Further studies are
needed to explore the role of iron metabolism in the
myocardial reverse remodeling that follows kidney
transplantation.
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1786these parameters. The study did not assess for
symptoms and functional status, or metabolic pa-
rameters, including iron studies, parathyroid hor-
mone, phosphorous, and calcium.
CONCLUSIONS
In kidney transplantationpatients, post-transplantation
improvement in anemia was an important factor
associated with the observed signiﬁcant reverse
remodeling and an independent factor associated
with reduced mortality. Importantly, we demonstrated
favorable survival in patients with pre-transplantation
LV dysfunction who underwent reverse remodeling.
Additional studies should analyze the prognostic
implications that these changes pose, and the ﬁndings
from this study, as well as others, should be taken into
consideration when determining criteria for kidney
transplantation candidacy.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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